|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C1orf109 |
Gene summary for C1ORF109 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C1orf109 | Gene ID | 54955 |
| Gene name | chromosome 1 open reading frame 109 | |
| Gene Alias | C1orf109 | |
| Cytomap | 1p34.3 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B4DRQ5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54955 | C1orf109 | P62T-E | Human | Esophagus | ESCC | 1.56e-16 | 3.36e-01 | 0.1302 |
| 54955 | C1orf109 | P65T-E | Human | Esophagus | ESCC | 5.53e-10 | 1.02e-01 | 0.0978 |
| 54955 | C1orf109 | P74T-E | Human | Esophagus | ESCC | 4.19e-17 | 4.43e-01 | 0.1479 |
| 54955 | C1orf109 | P75T-E | Human | Esophagus | ESCC | 1.89e-18 | 3.98e-01 | 0.1125 |
| 54955 | C1orf109 | P76T-E | Human | Esophagus | ESCC | 9.23e-10 | 2.13e-01 | 0.1207 |
| 54955 | C1orf109 | P79T-E | Human | Esophagus | ESCC | 1.44e-09 | 2.28e-01 | 0.1154 |
| 54955 | C1orf109 | P80T-E | Human | Esophagus | ESCC | 1.03e-22 | 6.08e-01 | 0.155 |
| 54955 | C1orf109 | P83T-E | Human | Esophagus | ESCC | 1.11e-13 | 3.86e-01 | 0.1738 |
| 54955 | C1orf109 | P84T-E | Human | Esophagus | ESCC | 1.18e-03 | 1.50e-01 | 0.0933 |
| 54955 | C1orf109 | P89T-E | Human | Esophagus | ESCC | 3.45e-04 | 2.97e-01 | 0.1752 |
| 54955 | C1orf109 | P91T-E | Human | Esophagus | ESCC | 5.22e-08 | 6.75e-01 | 0.1828 |
| 54955 | C1orf109 | P107T-E | Human | Esophagus | ESCC | 4.07e-18 | 4.39e-01 | 0.171 |
| 54955 | C1orf109 | P127T-E | Human | Esophagus | ESCC | 4.02e-07 | 6.57e-02 | 0.0826 |
| 54955 | C1orf109 | P128T-E | Human | Esophagus | ESCC | 8.00e-22 | 6.12e-01 | 0.1241 |
| 54955 | C1orf109 | P130T-E | Human | Esophagus | ESCC | 6.02e-23 | 4.26e-01 | 0.1676 |
| 54955 | C1orf109 | HCC1_Meng | Human | Liver | HCC | 5.22e-42 | 6.19e-02 | 0.0246 |
| 54955 | C1orf109 | HCC2_Meng | Human | Liver | HCC | 4.69e-05 | 2.91e-02 | 0.0107 |
| 54955 | C1orf109 | HCC2 | Human | Liver | HCC | 2.27e-06 | 1.68e+00 | 0.5341 |
| 54955 | C1orf109 | S014 | Human | Liver | HCC | 2.53e-13 | 4.28e-01 | 0.2254 |
| 54955 | C1orf109 | S015 | Human | Liver | HCC | 4.08e-16 | 5.90e-01 | 0.2375 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C1orf109 | SNV | Missense_Mutation | rs775429688 | c.152C>A | p.Ala51Asp | p.A51D | Q9NX04 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D8-A1JG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| C1orf109 | SNV | Missense_Mutation | rs138176961 | c.539N>A | p.Arg180Gln | p.R180Q | Q9NX04 | protein_coding | tolerated(0.49) | benign(0) | TCGA-CM-6676-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| C1orf109 | SNV | Missense_Mutation | novel | c.260N>G | p.Lys87Arg | p.K87R | Q9NX04 | protein_coding | tolerated(0.22) | benign(0.202) | TCGA-DC-5869-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C1orf109 | SNV | Missense_Mutation | c.455N>T | p.Ser152Leu | p.S152L | Q9NX04 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C1orf109 | SNV | Missense_Mutation | novel | c.562N>T | p.Asp188Tyr | p.D188Y | Q9NX04 | protein_coding | deleterious(0.01) | possibly_damaging(0.73) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C1orf109 | SNV | Missense_Mutation | c.455N>T | p.Ser152Leu | p.S152L | Q9NX04 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C1orf109 | SNV | Missense_Mutation | c.26N>T | p.Ala9Val | p.A9V | Q9NX04 | protein_coding | tolerated(0.16) | benign(0.007) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C1orf109 | SNV | Missense_Mutation | rs775429688 | c.152C>A | p.Ala51Asp | p.A51D | Q9NX04 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-D1-A16V-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| C1orf109 | SNV | Missense_Mutation | novel | c.478N>A | p.Leu160Ile | p.L160I | Q9NX04 | protein_coding | tolerated(0.05) | benign(0.019) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C1orf109 | SNV | Missense_Mutation | novel | c.325G>A | p.Val109Met | p.V109M | Q9NX04 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-CV-6953-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |